HANOI, VIETNAM, May 7, 2020 – (ACN Newswire) – On May 6th 2020, the Embassy of the Russian Federation in Vietnam and the Embassy of Ukraine in Vietnam signed a memorandum of agreement to receive 2,400 invasive ventilators for COVID-19 treatment given by Vingroup.

These ventilators are expected to be delivered from May 15th, 2020 to August 30th, 2020.

The given models include Vsmart VFS-410 and VFS-510 – the two "made in Vietnam" invasive ventilators which have been completed and manufactured entirely from the Vingroup ecosystem with a localization rate of up to 70%. This shows Vingroup's gratitude to the two countries which are closely attached to many generations of Vietnamese people and the country of Vietnam as well as the places where the Group's development originated.

Specifically, Vingroup will give Russia 1,000 VFS-410 ventilators and 500 VFS-510 ventilators; while giving Ukraine 600 VFS-410 ventilators and 300 VFS-510 ventilators. The estimated delivery time is from May 15th, 2020 to August 30th, 2020.

The VFS-410 and VFS-510 ventilators are currently being assessed by quality management agencies and the Medical Council of Vietnam, ensuring compliance with quality standards for product circulation in Vietnam. At the same time, Vingroup is promoting the supply of ventilator models for Russia and Ukraine to carry out quality inspection procedures in accordance with their current regulations. The Group will officially hand over 2,400 ventilators after being granted product circulation licenses by Russia and Ukraine.

Vsmart VFS-410 is a special upgrade of the first version of VFS-310 ventilator developed by Vingroup engineers from the community-shared design by Massachusetts Institute of Technology (MIT). This is an invasive ventilator based on turbine technology with similar features to high-end portable invasive ventilators on the market. Furthermore, the ventilator is provided with sensors that monitor and give warning about maintaining oxygen levels, positive end-expiratory pressure, measure patient breathing, and self-adjust to synchronize with this breath. The ventilator is compact, lightweight, and portable which can be used for ambulances or emergency cases at the scene and hospitals after Covid-19 pandemic is controlled.

VSmart VFS-510 subjects to technology transferred and improvement from a commonly used ventilator from U.S.-based Medtronic, the world's leading producer of breathing apparatus. VFS-510 is compact, lightweight, and portable with 6 flexible breathing modes that can be used for both adult and pediatric patients who need invasive or noninvasive breathing support as directed by their physicians.

Their international standard performance enable VFS-410 and VFS-510 to not only timely meet the immediate needs for COVID-19 treatment but also continue to be used effectively in intensive care unit (ICU) of medical facilities with long-term value and effectiveness.

Mr. Nguyen Viet Quang – Vice Chairman and CEO of Vingroup said that: "By giving 2,400 invasive ventilators, Vingroup hopes to actively contribute to the effective treatment of medical forces in Russia and Ukraine for patients and control of Covid-19 pandemic. This shows the gratitude of the Group's management to the two countries for their close connection with the startup process of Vingroup."

Up to now, Vingroup is one of the pioneer enterprises in Asia in sponsoring and supporting the fight against the COVID-19 pandemic with a total sponsorship fund of nearly VND 600 billion excluding funding for investment in manufacturing ventilators.

The successful production of "Made in Vietnam" ventilators in record time and proactive giving them to countries that are facing complex difficulties caused by COVID-19 continues to affirm the spirit of mutual affection – "the leaves protect tattered ones" and the tradition "when drinking water, think of its source" of the Vietnamese people.

Reference information:
As reported by the worldometers.info statistics, by 7am May 6th 2020, there are more than 3.7 million Covid-19 cases and nearly 258,000 deaths in the world. Russia is gradually becoming the currently hottest spot of COVID-19 pandemic, with a total of 155,370 SARS-CoV-2 confirmed cases and 1,451 deaths. While Ukraine's Ministry of Health reported a total of 12,697 COVID-19 confirmed cases and 316 deaths as of May 6th 2020.

Media contact: info@vingroup.net

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

SINGAPORE, Apr 24, 2020 – (ACN Newswire) – SGX-listed Singapore eDevelopment Ltd's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc., announced today that their suite of antiviral and medical technologies, co-owned with its partners, is valued at USD 592 Million (SGD 841 Million). Impact Biomedical's effective ownership of 64.53% in the suite of technologies equates to a value of USD 382 Million (SGD 542 Million). Following encouraging COVID-19 testing results, the groundbreaking technology was independently valued by recognized intellectual property valuation and licensing firm Destum Partners, known globally for its high level of expertise and capability in independently valuing and licensing pharmaceutical technology. The commercial assessment includes: 3F Biofragrance – a key component of the Open Air Defense Initiative, Equivir – an OTC medication with broad antiviral activity, and Linebacker – a broad-spectrum universal therapeutic. Continuing development of the COVID-19 research program is underway.

This research is part of a multi-year pandemic research program conducted by Impact Biomedical's research partner, GRDG Sciences, LLC ("GRDG"), which covers a wide range of solutions to global health issues to adhere to the principles and initiatives established by Project Bioshield and the Biomedical Advanced Research and Development Authority (BARDA). All three compounds were tested against a rigorous in vitro respiratory virus panel by GRDG, who utilized the non-clinical and pre-clinical services program offered by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Previous antimicrobial research was conducted at multiple independent laboratories. The technology consists of:

– 3F Antiviral Biofragrance – 3F Antiviral Biofragrance was designed for the Open Air Defense Initiative, a strategy to protect locations where large numbers of people gather or transit such as airports, containment areas, train stations, convention centers, hospitals, and ports of entry. The concept is rather than quarantine people from the virus, quarantine the virus from people. 3F Biofragrance technology also provides protection against mosquito-borne diseases such as Zika, Malaria and Dengue fever and is 10-fold more effective than DEET. 3F Mosquito uses other receptor modalities than traditional mosquito repellents to effectively blind humans to mosquitoes. The Open Air Defense Initiative was created as a solution for Event 201, a pandemic exercise conducted in 2019 by the Johns Hopkins Center for Health Security, the World Economic Forum and the Bill and Melinda Gates Foundation. Event 201 highlighted areas where public/private partnerships are vital to respond to a severe pandemic. 3F Antiviral Biofragrance is effective against E. coli, MRSA, Influenza, Rhinovirus, Tuberculosis, and COVID-19.

– Equivir – Equivir was created as a solution for Project Bioshield, a U.S. government program to conduct and support research and development activities for countermeasures in biological emergencies. Equivir is a patented OTC medication that has broad antiviral efficacy against multiple types of Influenza, Rhinovirus, Cholera, Ebola, and COVID-19.

– Linebacker – Linebacker was modeled to shadow the Panacea program created by the US Defense Advanced Research Projects Agency (DARPA). Panacea was a research program designed to provide novel, multi-target therapeutics for unmet physiological needs. Linebacker is a patented universal therapeutic medication with demonstrated effectiveness in neurological diseases including Parkinson's, multiple histotypes of cancer, and multiple pathogens such as MRSA, E. coli, Cholera, A. baumannii, Influenza, SARS, MERS, Malaria, and COVID-19.

– Laetose – Laetose is a reduced calorie low glycemic sugar replacement created to address the rising global problem of metabolic disorders and associated conditions.

Previous research identified the Angiotensin converting enzyme 2 ("ACE2") as the host receptor for SARS-CoV-2, the virus causing the COVID-19 pandemic. Molecular docking conducted by GRDG indicated that Linebacker and Equivir cause a conformational change and modulate the ACE-2 receptor and block three integral viral mechanisms for SARS-CoV-2 replication and infection: the viral spike interaction point, helicase, and protease on the ACE-2 receptor.

"This professional valuation further validates our technologies, allowing us to move to the next step of engaging in further collaborations to bring things up to speed" said Mr Chan Heng Fai, Executive Chairman of SeD.

GRDG's Chief Scientific Advisor is Dr. Roscoe M. Moore, Jr., the former United States Assistant Surgeon General and former Epidemic Intelligence Service Officer at Centers for Disease Control and Prevention or CDC. He said, "the multiple strategies developed by GRDG to fight global healthcare issues including the recent COVID-19 pandemic are important advances in science to potentially save many lives."

Also advising GRDG is Lieutenant Colonel William H. Lyerly Jr., retired Career Senior Executive/Scientific Professional from the U.S. Department of Homeland Security and retired U.S. Army Medical Service Corps Officer. Lieutenant Colonel Lyerly also served as a senior official in the U.S. Department of Health and Human Services, the U.S. Agency for International Development, and the U.S. Executive Office of the President (White House). Lieutenant Colonel Lyerly said, "GRDG's multi-prong strategy to develop and validate different technologies for threats to health is a positive step forward to address many unmet medical needs including the application of evolving novel interventions to address the current Coronavirus pandemic."

Daryl Thompson, Director of Scientific Initiatives and founder of GRDG said, "We are proud of the Impact Biomedical research team and the successful accomplishment of a 5 year research and development project focused on the identification and proving of viable biodefense countermeasures as outlined in the Pandemic and All Hazards Preparedness Act established in 2006.

"Moving ahead we are looking forward to another series of research focused on developing global viral mitigation and control technologies for scenarios such as the current COVID-19 outbreak, the development of novel antiviral therapeutics, as well as addressing solutions for the impending 'patent cliff' crisis expected in 2024.

"Impact Biomedical and its research partner Global Research and Discovery Group Sciences will work with leading global policy makers to establish specially created research teams focused exclusively on 'difficult to achieve' or nearly impossible projects utilizing lessons learned from our previous projects."

Shareholders and potential investors of SeD are advised to read this Press Release and any further announcements made by SeD carefully. Shareholders and potential investors of SeD are advised to refrain from taking any action with respect to their securities in SeD which may be prejudicial to their interests, and to exercise caution when dealing in the securities of SeD. Shareholders and potential investors of SeD should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

About Singapore eDevelopment Limited
Incorporated on 9 September 2009 and listed on the Singapore Exchange in July 2010, Singapore eDevelopment Limited is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg or email contact@sed.com.sg.

About Impact BioMedical, Inc.
Impact BioMedical, Inc. ("Impact BioMedical") is a wholly-owned direct subsidiary of Global BioMedical Pte. Ltd., which in turn is a wholly-owned direct subsidiary of Singapore eDevelopment Limited, a company listed on the Singapore Exchange. Impact BioMedical strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. By tapping into the scientific expertise of GRDG Sciences, LLC. and Australian Exchange-listed Holista CollTech Limited, Impact BioMedical pledges to undertake a concerted effort in the R&D, drug discovery and development for the prevention, inhibition, and treatment of neurological, oncological and immuno related diseases.

About GRDG Sciences, LLC.
GRDG Sciences, LLC is an advanced research team formed in Florida by drug discovery research scientist, Daryl Thompson. For more information, please visit: http://www.globalrdg.com.

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

KUALA LUMPUR / PERTH, Apr 22, 2020 – (ACN Newswire) – Path-Away(R), a plant-based natural active ingredient used in the alcohol-free NatShield(TM) hand sanitiser developed by Malaysia-based and Australia-listed Holista CollTech (ASX: HCT), has been tested by a leading U.K. bio-safety laboratory to be more than 99.99% effective against a surrogate of the COVID-19 novel coronavirus, Holista said today.

Holista announced that the positive results of the test by an internationally recognised laboratory is a major step in its efforts to help prevent the spread of the pandemic that so far has infected more than 2.4 million people and killed over 625,000 people worldwide.

Path-Away(R) is developed by Global Infections Control Consultants LLC ("GICC LLC"), headquartered in South Carolina, United States. Holista is the global distributor of Path-Away(R) under the trademark NatShield(TM) hand sanitiser containing 3% of Path-Away(R).

While Path-Away(R) had already been proven previously to be effective as a broad-spectrum sanitiser capable of killing a range of viruses, bacteria and fungi without the use of alcohol or toxic chemicals, both GICC LLC and Holista decided to subject it to tests by a recognised bio-safety laboratory using protocols that are accepted internationally.

Path-Away(R) works by attaching itself to the virus and weakening its walls. It inhibits its ability to take up amino acids – their basic building block. This forces the viruses to clump together, in the process of killing themselves, almost instantly. The compound is environmentally safe with very low toxicity and does not harm humans and pets.

The latest U.K. test results confirm that Path-Away(R) in Natshield(TM) has an efficacy of at 4.17Log (99.99% efficacy) within a minute against the feline coronavirus (a surrogate of COVID-19) when tested at a concentration of 3%. This means that 99.99% of the virus is killed within a minute of exposure to Natshield(TM) – a huge attribute to an all-natural sanitizer that is free of alcohol and chemicals.

The feline coronavirus is increasingly used in international testing as a surrogate to COVID-19 as there are huge bio-security and safety concerns for laboratories handling the actual virus. In line with regulations of Australia's Therapeutic Goods Administration, claims of efficacy against COVID-19 as a disinfectant must be made with surrogate human or animal coronaviruses including the feline coronavirus. The U.K. laboratory tested Path-Away(R) against the feline coronavirus (Realm: Riboviria; Order: Nidovirales; Family: Coronaviridae; Genus: Betacoronavirus; Species: COVID-19).

The deadly novel coronavirus has been given the official name of Severe Acute Respiratory Syndrome Coronavirus 2 ("SARS-CoV-2") by the International Committee for Taxonomy of Viruses, while the World Health Organisation has named the disease caused by the virus as Coronavirus disease 2019 ("COVID-19").

COVID-19's ability to survive on surfaces for up to nine days while remaining aerosolised, or airborne, is among the reasons attributed for its rapid global spread in recent weeks. In view of rising infections and fatalities due to the pandemic, GICC LLC and Holista expedited the tests to facilitate specific claims against COVID-19 for Natshield(TM).

"Path-Away(R) was subjected to high international standards of testing against COVID-19 and we are elated by the results. We hope these results will advance the global efforts to combat the spread of this coronavirus, future contagions and even the common flu by something very natural and environmentally friendly," said Dr Arthur V. Martin, President of GICC LLC.

"This is highly significant for NatShield(TM). The results have satisfied the European standard that applies to areas and situations where disinfection is medically indicated. This scientific validation means that NatShield(TM) can be used to sanitise the hands without the need for rinsing, can be applied to the face and even inside the nose without irritation and is not harmful even if swallowed. It may also be sprayed safely to sanitise a person's immediate surrounding space, without any negative effects," said Dr Rajen Manicka, CEO of Holista.

Holista and GICC LLC have issued instructions to commence further tests on Path-Away(R) to assess its efficacy against COVID-19 via the more rigorous direct inoculation method. This additional testing is being conducted at biosafety laboratory approved by the U.S. Centers for Disease Control ("CDC"). Results will be released once the testing procedure is completed based on the current work schedule.

Path-Away(R)'s ingredients are Generally Regarded As Safe ("GRAS") certified, approved by the Food and Drug Administration ("FDA") and exempted by the Environmental Protection Agency ("EPA") – all under the U.S. FIFRA 25(b) Code of Federal Regulations. It is listed in the U.S. Pharmacopeia ("USP") and has undergone successful USP-51 testing. Path-Away(R) is also approved by the American Food and Safety Authority and Environmental Protection Authority of New Zealand.

About Holista CollTech Ltd

Holista CollTech Ltd ("Holista") is a natural wellness company, the result of a merger between Holista Biotech Sdn Bhd and CollTech Australia Ltd. The company has 3 main divisions:
– Dietary supplements and personal care
– Food Ingredients
– Ovine collagen

Holista has a global collaboration for Path-Away(R), a plant-based solution that is proven to kill a broad spectrum of microbes. The all-natural alcohol-free solution is an active ingredient in Holista's proprietary hand sanitiser, NatShield(TM) that is sold under its personal care range.

Holista researches, develops, manufactures and markets "health-style" products to address the unmet and evolving needs of natural medicine. Holista's suite of ingredients includes low-GI baked products, reduced-sodium salts, low-fat fried foods and low-calorie sugar without compromising taste, odour and mouthfeel. Holista remains the only company to produce sheep (ovine) collagen using patented extraction methods. For more information, please refer to http://www.holistaco.com

Further Information About the U.K. Testing

The testing at the U.K. laboratory had commenced 12 March 2020 based on all accepted testing protocols needed to provide data for Holista and GICC LLC to make label claims specific to COVID-19, which was formerly referred to as "2019 novel coronavirus" or "2019-nCoV".

The testing panel also included other members of the coronavirus family such as SARS and the more common human influenza virus. The testing was completed in April 2020.

The test in the U.K. laboratory used the standard method BS EN 14476. This describes a test method and the minimum requirements for virucidal activity of a chemical disinfectant and antiseptic products. This European Standard applies to products that are used in the medical area in the fields of hygienic handrub, hygienic handwash, instrument disinfection by immersion, surface disinfection by wiping, spraying, flooding or other means and textile disinfection.

This European standard applies to areas and situations where disinfection is medically indicated
– in patient care (for example: In hospitals, in community medical facilities)
– in dental institutions or in clinics of schools, of kindergartens and of nursing homes
– in the workplace and in the home
– may also include services such as laundries and kitchens supplying products directly for patients

Outline of Test Method (Obligatory Test Conditions)

A sample of the test product is added to a test suspension of viruses in a solution of interfering substance. The mixture is maintained at one of the temperatures and contact times specified in the standard. At the end of this contact time, a portion is taken. The virucidal action in this portion is immediately suppressed by a validated method. The dilutions are transferred into cell culture units either using monolayer or cell suspension. Infectivity tests are done either by plaque test or quantal tests.

After incubation, the titres of infectivity are calculated according to Spearman and Kaber or by plaque counting. Reduction of virus infectivity is calculated from differences of lg virus titres before (virus control) and after treatment with the product. The standard minimum spectrum of test organisms is Poliovirus, Adenovirus and Murine Norovirus.

The test used the standard method BS EN 14476. This describes a test method and the minimum requirements for virucidal activity of a chemical disinfectant and antiseptic products. This European Standard applies to products that are used in the medical area in the fields of hygienic handrub, hygienic handwash, instrument disinfection by immersion, surface disinfection by wiping, spraying, flooding or other means and textile disinfection.

This European standard applies to areas and situations where disinfection is medically indicated
– in patient care (for example: In hospitals, in community medical facilities)
– in dental institutions or in clinics of schools, of kindergartens and of nursing homes
– in the workplace and in the home
– may also include services such as laundries and kitchens supplying products directly for patients

Acceptance Criteria

The product when tested as above shall demonstrate at least a 4 log10 reduction against the test virus. The test is deemed valid where all control requirements are met.

Test Result

The test product received has achieved a >4-log reduction when tested under the condition stipulated in this report, against Feline coronavirus (surrogate of SARS-CoV2) when tested at a concentration of neat(3%).

4 Log Reduction

Scientists use a logarithmic scale to see the growth of virus. Log reduction stands for a 10-fold (or one decimal point) reduction in virus, meaning the disinfectant reduces the number of live viruses by 90 percent for every step of the division. A 4-log kill reduces the colony or viruses by a 99.99% reduction.

Media Contact:
holista@wer1.net (+65 67374844)
karishma@wer1.net (+65 84792656)

Corporate Affairs & Business Opportunities
Dr Rajen Manicka: rajen.m@holistaco.com

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

KUALA LUMPUR / PERTH, Apr 21, 2020 – (ACN Newswire) – Path-Away(R), a plant-based natural active ingredient used in the alcohol-free NatShield(TM) hand sanitiser developed by Malaysia-based and Australia-listed Holista CollTech (ASX: HCT), has been tested by a leading U.K. bio-safety laboratory to be more than 99.99% effective against a surrogate of the COVID-19 novel coronavirus, Holista said today.

Holista announced that the positive results of the test by an internationally recognised laboratory is a major step in its efforts to help prevent the spread of the pandemic that so far has infected more than 2.4 million people and killed over 625,000 people worldwide.

Path-Away(R) is developed by Global Infections Control Consultants LLC ("GICC LLC"), headquartered in South Carolina, United States. Holista is the global distributor of Path-Away(R) under the trademark NatShield(TM) hand sanitiser containing 3% of Path-Away(R).

While Path-Away(R) had already been proven previously to be effective as a broad-spectrum sanitiser capable of killing a range of viruses, bacteria and fungi without the use of alcohol or toxic chemicals, both GICC LLC and Holista decided to subject it to tests by a recognised bio-safety laboratory using protocols that are accepted internationally.

Path-Away(R) works by attaching itself to the virus and weakening its walls. It inhibits its ability to take up amino acids – their basic building block. This forces the viruses to clump together, in the process of killing themselves, almost instantly. The compound is environmentally safe with very low toxicity and does not harm humans and pets.

The latest U.K. test results confirm that Path-Away(R) in Natshield(TM) has an efficacy of at 4.17Log (99.99% efficacy) within a minute against the feline coronavirus (a surrogate of COVID-19) when tested at a concentration of 3%. This means that 99.99% of the virus is killed within a minute of exposure to Natshield(TM) – a huge attribute to an all-natural sanitizer that is free of alcohol and chemicals.

The feline coronavirus is increasingly used in international testing as a surrogate to COVID-19 as there are huge bio-security and safety concerns for laboratories handling the actual virus. In line with regulations of Australia's Therapeutic Goods Administration, claims of efficacy against COVID-19 as a disinfectant must be made with surrogate human or animal coronaviruses including the feline coronavirus. The U.K. laboratory tested Path-Away(R) against the feline coronavirus (Realm: Riboviria; Order: Nidovirales; Family: Coronaviridae; Genus: Betacoronavirus; Species: COVID-19).

The deadly novel coronavirus has been given the official name of Severe Acute Respiratory Syndrome Coronavirus 2 ("SARS-CoV-2") by the International Committee for Taxonomy of Viruses, while the World Health Organisation has named the disease caused by the virus as Coronavirus disease 2019 ("COVID-19").

COVID-19's ability to survive on surfaces for up to nine days while remaining aerosolised, or airborne, is among the reasons attributed for its rapid global spread in recent weeks. In view of rising infections and fatalities due to the pandemic, GICC LLC and Holista expedited the tests to facilitate specific claims against COVID-19 for Natshield(TM).

"Path-Away(R) was subjected to high international standards of testing against COVID-19 and we are elated by the results. We hope these results will advance the global efforts to combat the spread of this coronavirus, future contagions and even the common flu by something very natural and environmentally friendly," said Dr Arthur V. Martin, President of GICC LLC.

"This is highly significant for NatShield(TM). The results have satisfied the European standard that applies to areas and situations where disinfection is medically indicated. This scientific validation means that NatShield(TM) can be used to sanitise the hands without the need for rinsing, can be applied to the face and even inside the nose without irritation and is not harmful even if swallowed. It may also be sprayed safely to sanitise a person's immediate surrounding space, without any negative effects," said Dr Rajen Manicka, CEO of Holista.

Holista and GICC LLC have issued instructions to commence further tests on Path-Away(R) to assess its efficacy against COVID-19 via the more rigorous direct inoculation method. This additional testing is being conducted at biosafety laboratory approved by the U.S. Centers for Disease Control ("CDC"). Results will be released once the testing procedure is completed based on the current work schedule.

Path-Away(R)'s ingredients are Generally Regarded As Safe ("GRAS") certified, approved by the Food and Drug Administration ("FDA") and exempted by the Environmental Protection Agency ("EPA") – all under the U.S. FIFRA 25(b) Code of Federal Regulations. It is listed in the U.S. Pharmacopeia ("USP") and has undergone successful USP-51 testing. Path-Away(R) is also approved by the American Food and Safety Authority and Environmental Protection Authority of New Zealand.

About Holista CollTech Ltd

Holista CollTech Ltd ("Holista") is a natural wellness company, the result of a merger between Holista Biotech Sdn Bhd and CollTech Australia Ltd. The company has 3 main divisions:
– Dietary supplements and personal care
– Food Ingredients
– Ovine collagen

Holista has a global collaboration for Path-Away(R), a plant-based solution that is proven to kill a broad spectrum of microbes. The all-natural alcohol-free solution is an active ingredient in Holista's proprietary hand sanitiser, NatShield(TM) that is sold under its personal care range.

Holista researches, develops, manufactures and markets "health-style" products to address the unmet and evolving needs of natural medicine. Holista's suite of ingredients includes low-GI baked products, reduced-sodium salts, low-fat fried foods and low-calorie sugar without compromising taste, odour and mouthfeel. Holista remains the only company to produce sheep (ovine) collagen using patented extraction methods. For more information, please refer to http://www.holistaco.com

Further Information About the U.K. Testing

The testing at the U.K. laboratory had commenced 12 March 2020 based on all accepted testing protocols needed to provide data for Holista and GICC LLC to make label claims specific to COVID-19, which was formerly referred to as "2019 novel coronavirus" or "2019-nCoV".

The testing panel also included other members of the coronavirus family such as SARS and the more common human influenza virus. The testing was completed in April 2020.

The test in the U.K. laboratory used the standard method BS EN 14476. This describes a test method and the minimum requirements for virucidal activity of a chemical disinfectant and antiseptic products. This European Standard applies to products that are used in the medical area in the fields of hygienic handrub, hygienic handwash, instrument disinfection by immersion, surface disinfection by wiping, spraying, flooding or other means and textile disinfection.

This European standard applies to areas and situations where disinfection is medically indicated
– in patient care (for example: In hospitals, in community medical facilities)
– in dental institutions or in clinics of schools, of kindergartens and of nursing homes
– in the workplace and in the home
– may also include services such as laundries and kitchens supplying products directly for patients

Outline of Test Method (Obligatory Test Conditions)

A sample of the test product is added to a test suspension of viruses in a solution of interfering substance. The mixture is maintained at one of the temperatures and contact times specified in the standard. At the end of this contact time, a portion is taken. The virucidal action in this portion is immediately suppressed by a validated method. The dilutions are transferred into cell culture units either using monolayer or cell suspension. Infectivity tests are done either by plaque test or quantal tests.

After incubation, the titres of infectivity are calculated according to Spearman and Kaber or by plaque counting. Reduction of virus infectivity is calculated from differences of lg virus titres before (virus control) and after treatment with the product. The standard minimum spectrum of test organisms is Poliovirus, Adenovirus and Murine Norovirus.

The test used the standard method BS EN 14476. This describes a test method and the minimum requirements for virucidal activity of a chemical disinfectant and antiseptic products. This European Standard applies to products that are used in the medical area in the fields of hygienic handrub, hygienic handwash, instrument disinfection by immersion, surface disinfection by wiping, spraying, flooding or other means and textile disinfection.

This European standard applies to areas and situations where disinfection is medically indicated
– in patient care (for example: In hospitals, in community medical facilities)
– in dental institutions or in clinics of schools, of kindergartens and of nursing homes
– in the workplace and in the home
– may also include services such as laundries and kitchens supplying products directly for patients

Acceptance Criteria

The product when tested as above shall demonstrate at least a 4 log10 reduction against the test virus. The test is deemed valid where all control requirements are met.

Test Result

The test product received has achieved a >4-log reduction when tested under the condition stipulated in this report, against Feline coronavirus (surrogate of SARS-CoV2) when tested at a concentration of neat(3%).

4 Log Reduction

Scientists use a logarithmic scale to see the growth of virus. Log reduction stands for a 10-fold (or one decimal point) reduction in virus, meaning the disinfectant reduces the number of live viruses by 90 percent for every step of the division. A 4-log kill reduces the colony or viruses by a 99.99% reduction.

Media Contact:
holista@wer1.net (+65 67374844)
karishma@wer1.net (+65 84792656)

Corporate Affairs & Business Opportunities
Dr Rajen Manicka: rajen.m@holistaco.com

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com